standard treatment of elderly patients with aml & evaluating idh inhibitors in younger patients
Published 1 year ago • 129 plays • Length 3:14Download video MP4
Download video MP3
Similar videos
-
1:50
the challenge of treating elderly patients with aml with venetoclax plus azacitidine
-
0:53
ukall60 : identifying the standard of care for elderly patients with all
-
3:25
treatment approaches for elderly/unfit patients with aml ineligible for intensive chemotherapy
-
3:59
treatment cessation using venetoclax-based therapy for older patients with aml
-
1:59
the efficacy of venetoclax-based salvage therapy in patients with previously treated r/r aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:30
real-world outcomes of venetoclax azacitidine versus intensive chemotherapy in newly diagnosed aml
-
4:17
the benefits of being pro-active in your aml care
-
1:31:30
2021 new and emerging treatment options: aml and minimal residual disease in blood cancers
-
4:29
treatment strategies in older patients with aml
-
11:35
optimization of standard aml treatment: apl advances, adverse cytogenetics & post-remission therapy
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
2:37
maintenance venetoclax and 5-azacytidine in patients with aml
-
5:01
treatment options for high-risk aml
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml
-
3:07
induction & maintenance therapy in elderly patients with mcl: insights from the mcl-r2 elderly trial
-
1:19
new treatments for aml
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
3:16
improving upon the standard of care for patients with richter’s transformation
-
1:03
the importance of geriatric assessment and patient selection for sct in aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml